Newamsterdam pharma company n.v.NAMSW.US Overview
US StockHealthcare
(No presentation for NAMSW)
NAMSW Overall Performance
NAMSW AI Analysis & Strategy
NAMSW Recent Performance
-
Newamsterdam pharma company n.v.
0.81%
Avg of Sector
-1.14%
S&P500
NAMSW PowerScanner
NAMSW Key Information
NAMSW Valuation Metrics
NAMSW Earnings Table
NAMSW Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.